普华和顺(01358)公布，2025年10月14日耗资43.8万港元回购30万股股份。 ...

智通财经APP讯，普华和顺(01358)公布，2025年10月14日耗资43.8万港元回购30万股股份。 ...

格隆汇10月14日丨普华和顺(01358.HK)发布公告，2025年10月14日耗资43.8万港元回购30万股，回购价 格每股1.46港元。 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 呈交日期： 2025年10月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01358 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | | | | | | 事件 | | 佔有關事件前的現有已發 | | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | 行股份（ ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01358 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.0001 USD | | 500,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 5,000,000,000 | USD | | 0.0001 USD | | 500,000 | 本月底法定/註冊股本總額： USD 500,000 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫 ...

Core Viewpoint - PwC announced that Sichuan Ruijian Medical's financial statements are set to expire on December 31, 2024, leading the company to voluntarily suspend its subsequent listing review process with the Beijing Stock Exchange [1] Group 1 - Sichuan Ruijian Medical submitted an application to suspend its listing review process on September 26, 2025 [1] - The review status of the subsequent listing has been adjusted to "suspended" by the Beijing Stock Exchange [1] - On September 30, 2025, Sichuan Ruijian Medical received a second round inquiry letter regarding its public offering and listing application from the Beijing Stock Exchange [1] Group 2 - The subsequent listing and its review process have not been terminated, and related matters are still ongoing [1] - Sichuan Ruijian Medical's shares will continue to be suspended on the National Equities Exchange and Quotations system [1] - The company will issue further announcements in accordance with listing rules as necessary [1]

Core Viewpoint - PwC announced that Sichuan Ruijian Medical's financial statements are set to expire on December 31, 2024, leading the company to voluntarily suspend its listing review process with the Beijing Stock Exchange [1] Group 1 - Sichuan Ruijian Medical submitted an application to suspend its subsequent listing review process on September 26, 2025 [1] - The review status of the subsequent listing has been adjusted to "suspended" by the Beijing Stock Exchange [1] - On September 30, 2025, Sichuan Ruijian Medical received a second round inquiry letter regarding its public offering and listing application from the Beijing Stock Exchange [1] Group 2 - The subsequent listing and its review process have not been terminated, and related matters are still ongoing [1] - Sichuan Ruijian Medical's shares will continue to be suspended from trading on the National Equities Exchange and Quotations system [1] - The company will issue further announcements in accordance with listing rules as necessary [1]

Core Points - PwC announced that Sichuan Ruijian Medical's financial statements are set to expire on December 31, 2024, leading the company to voluntarily apply for a suspension of its subsequent listing review process on September 26, 2025 [1] - As of the announcement date, the review status for the subsequent listing has been adjusted to suspended by the Beijing Stock Exchange [1] - On September 30, 2025, Sichuan Ruijian Medical received a second round inquiry letter regarding its application for public stock issuance and listing on the Beijing Stock Exchange [1] - The subsequent listing and its review process have not been terminated, and related matters are still ongoing, resulting in the company's shares being suspended on the National Equities Exchange and Quotations system [1] - The company will issue further announcements in accordance with listing rules as necessary [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 本公告僅供參考，並不構成且無意用作在香港、中華人民共和國或其他地區收購、購買或認購證券的邀請或 要約，或在前述地區出售證券的要約或招攬購買證券的要約。 PW MEDTECH GROUP LIMITED 普 華 和 順 集 團 公 司 （ 於開曼群島註冊成立之有限公司） （股份代號：1358） 本公告乃由普華和順集團公司（「本公司」）自願作出。 股東 及潛在投 資者務 請注意 ，其後上 市受限 於（ 其中包 括 ）當前市況 及相關 機關（ 包括 中國 證 監 會 及 北 京 證 券 交 易 所 ）批 准 。 因 此 ， 股 東 及 潛 在 投 資 者 務 請 知 悉 本 公 司 並 不 保 證 其 後 上市定必落實進行及其落實時間。股東及潛在投資者於買賣本公司證券時務請審慎行事。 承董事會命 普華和順集團公司 主席兼首席執行官 張月娥 香港，二零二五年九月三十日 於本公告日期，董事會由一名執行董事張月娥女 ...

Core Viewpoint - PwC Holdings (01358) announced the cancellation of a total of 8.733 million repurchased shares, effective September 30, 2025 [1] Company Summary - The company has decided to cancel shares that were previously repurchased, indicating a strategic move to manage its capital structure [1]